Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adamis Pharmaceuticals has recruited first patient in a Phase 1/2a study evaluating APC-100 as a treatment for castrate-resistant prostate cancer (CRPR).
Subscribe to our email newsletter
The trial aims to investigate each patient for toxicity, biochemical (Prostate Specific Antigen), radiographic and clinical responses.
Previosly, APC-100 has been shown to have higher therapeutic activity than the current marketed Standard of Care anti-androgens.
Adamis president and CEO Dennis Carlo said moving APC-100 into human clinical trials is yet another major milestone for the company.
"Because of its mechanism of action, APC-100 can be used either as a stand-alone treatment or be used to enhance the activity of existing or upcoming new anti-prostate cancer products," Carlo said.